Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial

医学 阿米卡星 安慰剂 临床终点 辅助治疗 肺炎 抗生素 临床试验 重症监护 内科学 麻醉 重症监护医学 替代医学 病理 微生物学 生物
作者
Michael S. Niederman,Jeff D. Alder,Matteo Bassetti,Francis Boateng,Bin Cao,Kevin J. Corkery,Rajiv Dhand,Keith S. Kaye,Robert Lawatscheck,Patrick McLeroth,David P. Nicolau,Chen Wang,G. Christopher Wood,Richard G. Wunderink,Jean E. Chastre
出处
期刊:Lancet Infectious Diseases [Elsevier BV]
卷期号:20 (3): 330-340 被引量:141
标识
DOI:10.1016/s1473-3099(19)30574-2
摘要

Treatment of ventilated pneumonia is often unsuccessful, even when patients are treated according to established guidelines. Therefore, we aimed to investigate the efficacy of the combination drug device Amikacin Inhale as an adjunctive therapy to intravenous standard-of-care antibiotics for pneumonia caused by Gram-negative pathogens in intubated and mechanically ventilated patients.INHALE was a prospective, double-blind, randomised, placebo-controlled, phase 3 study comprising two trials (INHALE 1 and INHALE 2) done in 153 hospital intensive-care units in 25 countries. Eligible patients were aged 18 years or older; had pneumonia that had been diagnosed by chest radiography and that was documented as being caused by or showing two risk factors for a Gram-negative, multidrug-resistant pathogen; were intubated and mechanically ventilated; had impaired oxygenation within 48 h before screening; and had a modified Clinical Pulmonary Infection Score of at least 6. Patients were stratified by region and disease severity (according to their Acute Physiology and Chronic Health Evaluation [APACHE] II score) and randomly assigned (1:1) via an interactive voice-recognition system to receive 400 mg amikacin (Amikacin Inhale) or saline placebo, both of which were aerosolised, administered every 12 h for 10 days via the same synchronised inhalation system, and given alongside standard-of-care intravenous antibiotics. All patients and all staff involved in administering devices and monitoring outcomes were masked to treatment assignment. The primary endpoint, survival at days 28-32, was analysed in all patients who received at least one dose of study drug, were infected with a Gram-negative pathogen, and had an APACHE II score of at least 10 at diagnosis. Safety analyses were done in all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, numbers NCT01799993 and NCT00805168.Between April 13, 2013, and April 7, 2017, 807 patients were assessed for eligibility and 725 were randomly assigned to Amikacin Inhale (362 patients) or aerosolised placebo (363 patients). 712 patients received at least one dose of study drug (354 in the Amikacin Inhale group and 358 in the placebo group), although one patient assigned to Amikacin Inhale received placebo in error and was included in the placebo group for safety analyses. 508 patients (255 in the Amikacin Inhale group and 253 in the placebo group) were assessed for the primary endpoint. We found no between-group difference in survival: 191 (75%) patients in the Amikacin Inhale group versus 196 (77%) patients in the placebo group survived until days 28-32 (odds ratio 0·841, 95% CI 0·554-1·277; p=0·43). Similar proportions of patients in the two treatment groups had a treatment-emergent adverse event (295 [84%] of 353 patients in the Amikacin Inhale group vs 303 [84%] of 359 patients in the placebo group) or a serious treatment-emergent adverse event (101 [29%] patients vs 97 [27%] patients).Our findings do not support use of inhaled amikacin adjunctive to standard-of-care intravenous therapy in mechanically ventilated patients with Gram-negative pneumonia.Bayer AG.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
南川完成签到,获得积分10
刚刚
十九完成签到,获得积分10
1秒前
若曦完成签到,获得积分10
1秒前
丘比特的应助被hikkinouta采纳,获得10
2秒前
3秒前
敖江风云完成签到,获得积分10
3秒前
LiuZiqi发布了新的文献求助10
4秒前
shinez发布了新的文献求助10
4秒前
Jasper的应助被nostalgic采纳,获得10
4秒前
4秒前
4秒前
AB完成签到,获得积分10
4秒前
英勇棉花糖完成签到,获得积分10
5秒前
Laputa完成签到,获得积分10
5秒前
5秒前
pangpang发布了新的文献求助10
6秒前
天天快乐的应助被cjh采纳,获得10
6秒前
学霸业的应助被小古采纳,获得10
6秒前
池林完成签到,获得积分10
6秒前
chen完成签到,获得积分10
7秒前
cz完成签到,获得积分10
8秒前
whenimdrunk发布了新的文献求助10
8秒前
娇娇老师发布了新的文献求助10
9秒前
深情安青的应助被超级故事采纳,获得10
9秒前
lms完成签到 ,获得积分20
10秒前
li完成签到,获得积分10
12秒前
所所的应助被呆瓜子采纳,获得10
12秒前
小古完成签到,获得积分20
12秒前
ufofly730完成签到 ,获得积分0
12秒前
uu完成签到,获得积分10
14秒前
14秒前
Athos_1992完成签到,获得积分10
15秒前
盒盒怪完成签到,获得积分10
15秒前
科研通AI6.3的应助被曾经凌萱采纳,获得10
16秒前
詩翰发布了新的文献求助10
16秒前
Xiaoxiannv完成签到,获得积分10
16秒前
crazycathaha发布了新的文献求助10
17秒前
17秒前
企鹅完成签到,获得积分10
17秒前
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191366
求助须知:如何正确求助?哪些是违规求助? 9578238
关于积分的说明 21857620
捐赠科研通 7790721
什么是DOI,文献DOI怎么找? 3436607
关于科研通互助平台的介绍 2560359
邀请新用户注册赠送积分活动 2483340